- $2.13bn
- $2.01bn
- $233.66m
- 66
- 10
- 61
- 43
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 164.77 | ||
| PEG Ratio (f) | 2.38 | ||
| EPS Growth (f) | 226.37% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 13.26 | ||
| Price to Tang. Book | 13.32 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 9.11 | ||
| EV to EBITDA | 96.46 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 7.48% | ||
| Return on Equity | 11.57% | ||
| Operating Margin | 8.83% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.15 | 0.15 | 6.69 | 2.79 | 233.66 | 263.85 | 424.3 | 333.86% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Directors
- Michael Weiss CHM (55)
- Sean Power CFO (39)
- Laurence Charney LED (74)
- Yann Echelard IND (57)
- Kenneth Hoberman IND (56)
- Daniel Hume IND (54)
- William Kennedy IND (76)
- Sagar Lonial IND (54)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- May 18th, 1993
- Public Since
- December 14th, 1995
- No. of Shareholders
- 214
- No. of Employees
- 264
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 154,420,772
- Address
- 3020 Carrington Mill Blvd., Suite 475, MORRISVILLE, 27560-5435
- Web
- https://www.tgtherapeutics.com/
- Phone
- +1 2125544484
- Contact
- Jenna Bosco
- Auditors
- KPMG LLP
Upcoming Events for TGTX
TG Therapeutics Inc Annual Shareholders Meeting
TG Therapeutics Inc Annual Shareholders Meeting
Q2 2024 TG Therapeutics Inc Earnings Release
Similar to TGTX
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the TG Therapeutics share price?
As of Today at 19:21 UTC, shares in TG Therapeutics are trading at $13.78. This share price information is delayed by 15 minutes.
How has the TG Therapeutics share price performed this year?
Shares in TG Therapeutics last closed at $13.78 and the price had moved by -35.58% over the past 365 days. In terms of relative price strength the TG Therapeutics share price has underperformed the S&P500 Index by -46.39% over the past year.
What are the analyst and broker recommendations for TG Therapeutics?
The overall consensus recommendation for TG Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the TG Therapeutics dividend yield?
TG Therapeutics does not currently pay a dividend.
Does TG Therapeutics pay a dividend?
TG Therapeutics does not currently pay a dividend.
When does TG Therapeutics next pay dividends?
TG Therapeutics does not currently pay a dividend.
How do I buy TG Therapeutics shares?
To buy shares in TG Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of TG Therapeutics?
As of the previous close price of $13.78, shares in TG Therapeutics had a market capitalisation of $2.13bn.
Where are TG Therapeutics shares listed?
Here are the trading details for TG Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: TGTX
What kind of share is TG Therapeutics?
Based on an overall assessment of its quality, value and momentum TG Therapeutics is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a TG Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in TG Therapeutics is $30.43. That is 120.83% above the last closing price of $13.78.
Analysts covering TG Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.11 for the next financial year.
What is the trend in the TG Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like TG Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +73.32%.
As of the last closing price of $13.78, shares in TG Therapeutics were trading +0.13% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the TG Therapeutics PE Ratio?
The TG Therapeutics PE ratio based on its reported earnings over the past 12 months is 164.77. The shares last closed at $13.78.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of TG Therapeutics?
TG Therapeutics' management team is headed by:
- Michael Weiss - CHM
- Sean Power - CFO
- Laurence Charney - LED
- Yann Echelard - IND
- Kenneth Hoberman - IND
- Daniel Hume - IND
- William Kennedy - IND
- Sagar Lonial - IND